Znn3bq.jpeg
²é¿´: 1189  |  »Ø¸´: 7

honghao81_2007

½ð³æ (СÓÐÃûÆø)

[ÇóÖú] ´ó¼ÒË­ÓÐUSP35£¬°ïæ²éÒ»ÏÂÌæÄªßò°·(Temozolomide)µÄÖÊÁ¿±ê×¼£¡ÏÈллÁË¡£

¿ÉÒÔ·¢ÎÒÓÊÏähonghao81_2000@163.com
»Ø¸´´ËÂ¥
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

yugijiang

ľ³æ (ÖøÃûдÊÖ)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
honghao81_2007: ½ð±Ò+5, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸ 2012-07-09 15:18:02
³ÕÒÄ×ÓÆ¤: ½ð±Ò+1, лл½»Á÷¡£»¶Ó­³£À´Å¶¡£ 2012-07-10 11:34:09
Add the following:
Temozolomide
(tem'' oh zoe' loe mide).
  

C6H6N6O2194.15
Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-;   
3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide    [85622-93-1].
DEFINITION
Temozolomide contains NLT 98.0% and NMT 102.0% of C6H6N6O2, calculated on the as-is basis.
[Caution¡ªTemozolomide is cytotoxic. Great care should be taken to prevent inhaling particles of Temozolomide and exposure to the skin. ]
IDENTIFICATION
•  A. Infrared Absorption 197K
•  B. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.
ASSAY
[Note¡ªShake the solutions containing temozolomide to aid the dissolution. Do not sonicate. ]
•  Procedure
Solution A: 0.5% (v/v) of glacial acetic acid in water
Mobile phase: Solution A and methanol (96:4), containing 0.94 g/L of sodium 1-hexanesulfonate (0.005 M)
Diluent: Dimethylsulfoxide. [Note¡ªUse a freshly opened bottle. ]
Standard solution: 1.0 mg/mL of USP Temozolomide RS in Diluent
Sample solution: 1.0 mg/mL of Temozolomide in Diluent
Chromatographic system  
(See Chromatography 621, System Suitability.)
Mode: LC
Detector: UV 270 nm
Column: 4.6-mm ¡Á 15-cm; 5-µm packing L1
Flow rate: 1 mL/min
Injection size: 10 µL
System suitability  
Sample: Standard solution
Suitability requirements  
Relative standard deviation: NMT 1.5%
Tailing factor: NMT 1.9
Analysis  
Samples: Standard solution and Sample solution
Calculate the percentage of C6H6N6O2 in the portion of Temozolomide taken:
Result = (rU/rS) ¡Á (CS/CU) ¡Á 100
rU = = peak area from the Sample solution
rS = = peak area from the Standard solution
CS = = concentration of USP Temozolomide RS in the Standard solution (mg/mL)
CU = = concentration of Temozolomide in the Sample solution (mg/mL)

Acceptance criteria: 98.0%¨C102.0% calculated on the as-is basis
IMPURITIES
•  Residue on Ignition 281: NMT 0.1%
•  Heavy Metals, Method II231: NMT 30 ppm
•  Organic Impurities
[Note¡ªShake the solutions containing temozolomide to aid the dissolution. Do not sonicate. ]
Mobile phase, Diluent, and Sample solution: Proceed as directed in the Assay.
Standard solution: 2.0 µg/mL each of USP Temozolomide RS and USP Dacarbazine Related Compound A RS in Diluent
System suitability solution: 0.5 µg/mL each of USP Temozolomide RS and USP Dacarbazine Related Compound A RS in Diluent, from the Standard solution
Peak identification solution: Mix 5 mL of 0.1 N hydrochloric acid and 5 mL of 1.0 mg/mL of USP Temozolomide RS in Diluent. Heat the container for 1 h on a steam or boiling water bath. [Note¡ªThe preparation forms 2-azahypoxanthine, temozolomide acid, and dacarbazine related compound A. ]
Chromatographic system: Proceed as directed in the Assay, using a run time of NLT 3.2 times the retention time of the temozolomide peak.
System suitability  
Samples: Standard solution and System suitability solution
Suitability requirements  
Resolution: NLT 2.0 between the temozolomide and dacarbazine related compound A peaks, Standard solution
Relative standard deviation: NMT 10% for both dacarbazine related compound A and temozolomide peaks, System suitability solution
Analysis  
Samples: Sample solution, Standard solution, and Peak identification solution
Inject the Peak identification solution and identify the organic impurities according to the relative retention times given in Table 1.
Calculate the percentage of dacarbazine related compound A (free base) in the portion of Temozolomide taken:
Result = (rU/rS) ¡Á (CS/CU) ¡Á (Mr1/Mr2) ¡Á 100
rU = = peak area of dacarbazine related compound A from the Sample solution
rS = = peak area of dacarbazine related compound A from the Standard solution
CS = = concentration of USP Dacarbazine Related Compound A RS in the Standard solution (mg/mL)
CU = = concentration of Temozolomide in the Sample solution (mg/mL)
Mr1 = = molecular weight of dacarbazine related compound A (free base), 126.12
Mr2 = = molecular weight of dacarbazine related compound A (hydrochloride salt), 162.58

Calculate the percentage of any other individual impurity in the portion of Temozolomide taken:
Result = (rU/rS) ¡Á (CS/CU) ¡Á (1/F) ¡Á 100
rU = = peak area of each impurity from the Sample solution
rS = = peak area of temozolomide from the Standard solution
CS = = concentration of USP Temozolomide RS in the Standard solution (mg/mL)
CU = = concentration of Temozolomide in the Sample solution (mg/mL)
F = = relative response factor for each individual impurity (see Table 1)

Acceptance criteria: See Table 1. [Note¡ªDisregard any unspecified impurity peaks less than 0.05%. ]
Table 1
Name Relative
Retention
Time Relative
Response
Factor Acceptance
Criteria,
NMT (%)
2-Azahypoxanthinea 0.42 1.6 0.2
Temozolomide related compound Ab 0.53 1.0 0.5
Temozolomide acidc 0.84 1.0 0.1
Temozolomide 1.0 ¡ª ¡ª
Dacarbazine related compound A (free base)d 1.37 ¡ª 0.1
Any unspecified impurity ¡ª 1.0 0.10
Total impurities ¡ª ¡ª 0.8
a  4a,5-Dihydro-4H-imidazo[4,5-d][1,2,3]triazin-4-one.
b  4-Diazo-4H-imidazole-5-carboxamide.
c  3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid.
d  5-Aminoimidazole-4-carboxamide. It is a free base of dacarbazine related compound A.  

SPECIFIC TESTS
•  Water Determination, Method Ic921: NMT 0.4%
ADDITIONAL REQUIREMENTS
•  Packaging and Storage: Preserve in well-closed containers, and store at room temperature.
•  USP Reference Standards 11
USP Dacarbazine Related Compound A RS  
5-Aminoimidazole-4-carboxamide hydrochloride.
    C4H6N4O¡¤HCl        162.58
USP Temozolomide RS

» ±¾ÌûÒÑ»ñµÃµÄºì»¨£¨×îÐÂ10¶ä£©

2Â¥2012-07-09 14:03:22
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

honghao81_2007

½ð³æ (СÓÐÃûÆø)

ËÍÏÊ»¨Ò»¶ä
ÒýÓûØÌû:
2Â¥: Originally posted by yugijiang at 2012-07-09 14:03:22
Add the following:
Temozolomide
(tem'' oh zoe' loe mide).
  

C6H6N6O2194.15
Imidazo-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-;   
3,4-Dihydro-3-methyl-4-oxoimidazo-as- ...

Âé·³ÔÙÎÊÒ»ÏÂUSP35ÖÐÌæÄªßò°·ËùÓõ½µÄÉ«Æ×ÖùÐÅÏ¢£¬Ð»Ð»£¡
3Â¥2012-07-09 14:44:51
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

honghao81_2007

½ð³æ (СÓÐÃûÆø)

ÒýÓûØÌû:
2Â¥: Originally posted by yugijiang at 2012-07-09 14:03:22
Add the following:
Temozolomide
(tem'' oh zoe' loe mide).
  

C6H6N6O2194.15
Imidazo-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-;   
3,4-Dihydro-3-methyl-4-oxoimidazo-as- ...

²»ÖªµÀUSP35ÌæÄªßò°·Öù×ÓÐÅÏ¢ÊDz»ÊǺÍÏÂÃæµÄÒ»Ö£º
LGS#      Brand                Type of test      Additional information
L1    Spherisorb ODS-2        Assay and organic impurities        4.6mm*15cm£¬5¦Ìm
4Â¥2012-07-09 14:55:28
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

yugijiang

ľ³æ (ÖøÃûдÊÖ)

ÄÇÊÇÁíÍâÒ»±¾ÊéÉϵÄÏûÏ¢£¬ÒªÊշѵÄà¸
5Â¥2012-07-09 15:24:34
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

honghao81_2007

½ð³æ (СÓÐÃûÆø)

ÒýÓûØÌû:
5Â¥: Originally posted by yugijiang at 2012-07-09 15:24:34
ÄÇÊÇÁíÍâÒ»±¾ÊéÉϵÄÏûÏ¢£¬ÒªÊշѵÄà¸

ºÇºÇ£¬Ö»ÒªÄÜŪµ½ÎÒ¿ÉÒÔ¸ø½ð±ÒµÄ£¡
6Â¥2012-07-09 16:04:25
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

³ÕÒÄ×ÓÆ¤

°æÖ÷ (ÎÄ̳¾«Ó¢)

ÀÏÆ¦

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷



É«Æ×ÖùÐÅÏ¢

» ±¾ÌûÒÑ»ñµÃµÄºì»¨£¨×îÐÂ10¶ä£©

ÊØºòÔÚ·çÖеÄÄþ¾²¡£
7Â¥2012-07-10 11:38:12
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

honghao81_2007

½ð³æ (СÓÐÃûÆø)

ËÍÏÊ»¨Ò»¶ä
ÒýÓûØÌû:
7Â¥: Originally posted by ³ÕÒÄ×ÓÆ¤ at 2012-07-10 11:38:12
1a/2a/674536_1341891429_830.png

É«Æ×ÖùÐÅÏ¢

×òÌìûÓе磬¸Õ¿´µ½¡£°æÖ÷£¬·Ç³£¸Ðл£¡
8Â¥2012-07-11 08:59:07
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ honghao81_2007 µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ¿ÒÇëÓÐѧУÊÕÁô +8 ¿Â»´È» 2026-04-12 8/400 2026-04-17 09:34 by Öí»á·É
[¿¼ÑÐ] 300Çóµ÷¼Á +11 ³Èa777 2026-04-15 11/550 2026-04-16 22:43 by cfdbai
[»ù½ðÉêÇë] RY£ºÖйú²ú³öµÄ¿ÆÑ§À¬»øÂÛÎÄ£¬¾ø¶ÔÊýÁ¿ºÍ±ÈÀý¶¼ÊÀ½çµÚÒ» +7 zju2000 2026-04-14 18/900 2026-04-16 11:36 by »¶ÀÖËÌÒ¶Ýè
[¿¼ÑÐ] 322Çóµ÷¼Á +8 123°²¿µ 2026-04-12 15/750 2026-04-16 11:07 by Espannnnnol
[¿¼ÑÐ] Çóµ÷¼ÁÍÆ¼ö +8 СÄô°®Ñ§Ï° 2026-04-14 8/400 2026-04-16 07:22 by ѧԱJpLReM
[¿¼ÑÐ] Ò»Ö¾Ô¸AÇø211£¬22408 321Çóµ÷¼Á +6 ËæÐÄËùÓû¡î 2026-04-15 7/350 2026-04-15 21:45 by lbsjt
[¿¼ÑÐ] ҩѧÇóµ÷¼Á +11 RussHu 2026-04-12 13/650 2026-04-15 19:07 by zhuwenxu
[¿¼ÑÐ] ҩѧ305Çóµ÷¼Á +7 Â꿨°Í¿¨boom 2026-04-11 7/350 2026-04-15 13:21 by Î÷±±Íû¡ª·çɳ
[¿¼ÑÐ] ҩѧ305Çóµ÷¼Á +10 Â꿨°Í¿¨boom 2026-04-10 10/500 2026-04-14 15:55 by zs92450
[¿¼ÑÐ] 271Çóµ÷¼Á +35 2261744733 2026-04-11 41/2050 2026-04-14 15:36 by zs92450
[¿¼ÑÐ] Ò»Ö¾Ô¸»¦9£¬326ÇóÉúÎïѧµ÷¼Á +10 Áõīī 2026-04-13 10/500 2026-04-14 15:16 by zs92450
[¿¼ÑÐ] 085600²ÄÁÏÓ뻯¹¤329·ÖÇóµ÷¼Á +24 Ò¶zilin 2026-04-13 25/1250 2026-04-14 09:20 by ÊÔ¹ÜÆÆÁÑ
[¿¼ÑÐ] 293Çóµ÷¼Á +16 ÎÒ°®¸ßÊý¸ßÊý°®Î 2026-04-12 18/900 2026-04-13 21:47 by ѧԱJpLReM
[¿¼ÑÐ] BÇø0809 £¬ÊýÒ»Ó¢Ò»£¬290 Çóµ÷¼Á +3 ãöΫ1111 2026-04-12 4/200 2026-04-13 20:35 by ѧԱJpLReM
[¿¼ÑÐ] 302Çóµ÷¼Á +10 Ò×£¡? 2026-04-13 10/500 2026-04-13 19:04 by lbsjt
[¿¼ÑÐ] Ò»Ö¾Ô¸Õã´óÉúÎï325·ÖÇóµ÷¼Á +9 zysheng 2026-04-12 9/450 2026-04-12 22:31 by yuyin1233
[¿¼ÑÐ] Çóµ÷¼Á£¬Ò»Ö¾Ô¸²ÄÁÏ¿ÆÑ§Ó빤³Ì985£¬365·Ö£¬ +8 ²Ä»¯Àî¿É 2026-04-11 10/500 2026-04-12 08:42 by 852137818
[¿¼ÑÐ] Ò»Ö¾Ô¸Ïôó0856£¬306Çóµ÷¼Á +15 Bblinging 2026-04-11 15/750 2026-04-11 22:53 by 314126402
[¿¼ÑÐ] 283Çóµ÷¼Á 086004¿¼Ó¢¶þÊý¶þ +17 ÄǸöàà×Ó 2026-04-10 18/900 2026-04-11 16:27 by Ã÷Ô´ËʱÓÐ
[¿¼ÑÐ] Ò»Ö¾Ô¸985»úеѧ˶380Çóµ÷¼Á +5 ¹Ø¹ØöÂð¯10 2026-04-11 5/250 2026-04-11 10:10 by ÖªÄî¡£A
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û